G-protein coupled receptors are thought to transmit extracellular signals to the cytoplasm from their position on the cell surface. Some receptors including the metabotropic glutamate receptor 5, mGluR5, are also highly expressed on intracellular membranes where they serve unknown functions. Here we show that activation of cell surface versus intracellular mGluR5 results in unique Ca 2+ signatures leading to unique cellular responses. Specifically, activation of either cell surface or intracellular mGluR5 leads to JNK, CaMK, and CREB phosphorylation whereas activation of only intracellular mGluR5 leads to ERK1/2 and Elk-1 phosphorylation. Using pharmacological and genetic approaches, the present findings support a role for CaMKK in mediating mGluR5-dependent CREB phosphorylation whereas CaMKII is upstream of intracellular mGluR5-mediated Elk-1 phosphorylation. Consistent with models showing Elk-1 regulating cascades of gene expression, the known Elk-1 targets c-Fos and Egr1 were upregulated following intracellular mGluR5 activation whereas a representative non-Elk-1 target, c-Jun, was not. These findings emphasize that glutamate not only serves as a neurotransmitter for cell surface receptors but when transported into the cell, can also activate intracellular receptors such as mGluR5. Glutamate activation of intracellular mGluR5 serves an important role in the regulation of nuclear Ca 2+ , transcriptional activation and gene expression necessary for physiological processes such as synaptic plasticity.
G-protein coupled receptors are known for converting extracellular signals into intracellular responses. Some receptors however, are also localized on intracellular membranes where they perform unknown functions. For instance, 50-90% of the metabotropic glutamate receptor, mGluR5, which plays an active role in neuronal excitability, synaptic transmission, as well as in various neurological (anxiety, seizures, addiction) and neurodevelopmental (Fragile X syndrome, autism) disorders, is found on endoplasmic reticulum (ER) and nuclear membranes (1) (2) (3) .
In the striatum we have shown that mGluR5 is expressed on nuclear membranes where it can couple to G q/11 leading to phosphoinositide signaling and release of Ca 2+ from nuclear stores.
Moreover, results demonstrate that both sodium-dependent and independent transporters are involved in moving agonist across extra and intracellular membranes: inhibition of either transport system blocks agonist-induced nuclear Ca 2+ changes (4, 5) . Thus mechanisms exist whereby intracellular receptors like mGluR5 may be activated and in turn, trigger intracellular signal transduction processes.
What are the functional consequences of activating intracellular mGluR5? In the nucleus, Ca 2+ is generated by diffusion of cytosolic Ca 2+ waves through nuclear pore complexes (6) or by release from the lumen of the nuclear envelope (7, 8) . Presumably release of Ca 2+ from the nuclear lumen would amplify Ca 2+ signals crossing the nuclear envelope via the pore complex and/or independently generate nucleoplasmic Ca 2+ transients. Converging Ca 2+ transients may change the amplitude, duration and spatial characteristics of a Ca 2+ signal leading to differential activation of various transcriptional regulators and co-activators as well as their modifying enzymes (9) .
Two signal transduction pathways linking neuronal activity to transcriptional changes in the nucleus include Ca 2+ /calmodulin-dependent protein kinases (CaMK) and the mitogen activated protein kinase (MAPK) pathways via ERK1/2, p38MAPK, or SAPK/JNK (10) . Both pathways can lead to the phosphorylation of cyclic adenosine 3', 5'-monophosphate-responsive element binding protein (CREB) which plays an important role in survival and plasticity. Activation of the Ets transcription factor, Elk-1, also requires nuclear Ca 2+ (11) . A known target for MAPK signaling pathways, Elk-1 is an essential component of a ternary complex that activates the promoter of c-Fos and other immediate early genes (IEG) (12) . Studies have shown that mGluR5 activation leads to ERK1/2 phosphorylation and the upregulation of CREB and Elk-1, findings that reinforce the notion that mGluR5 modulates synaptic plasticity (13) . However whether these responses are due to cell surface or intracellular receptors is unclear.
To test the hypothesis that activation of intracellular mGluR5 leads to unique changes in signal transduction and subsequently gene expression, we used pharmacological, genetic and molecular tools. Here we show that activation of intracellular mGluR5 generates distinct Ca 2+ responses as well as downstream signaling cascades separate from their cell surface counterparts. These observations challenge the notion that cells only interact with their environment at the plasma membrane to bring about long term changes.
EXPERIMENTAL PROCEDURES
Materials. Drugs were as described (4, 5) or are listed in the Supplemental Data.
Cell Culture. Primary striatal cultures using neonatal rat or mouse pups were prepared, maintained and treated as detailed (4) . mGluR5 knock out mice were obtained from Dr. M.A. Schwarzchild (Massachusetts General Hospital, Boston, MA). Heterozygous mice were mated to produce wild-type, heterozygous, and homozygous mGluR5 deficient pups that were individually genotyped by PCR using DNA prepared from cortical tissue. Striatal tissue from each pup was processed separately.
Plasmids and Transfection. The "kinase dead" dominant-negative (dn) CaMK constructs dnCaMKI, dnCaMKIV, and dnCaMKK were obtained from Dr. T. R. Soderling (Oregon Health and Science University, Portland, OR). The dnCaMKII was obtained from Dr. U. Bayer (University of Colorado, Denver, CO). Cultures (50,000 cells/dish) were transfected with vectors expressing dnCaMKK (K71A, T108A, S458A),  dnCaMKI (K49E, T177A, IHQS286DDEE,  F307A), dnCaMKIV nuclear (T196A, K71E,  HMDT305DEDD) or dnCaMKII (K42M) fused to EGFP (14) or reporter gene constructs using Lipofectamine 2000 (Invitrogen Corporation, Carlsbad, CA). Treatment and subsequent analysis was done 24 hr post-transfection.
Immunocytochemistry and western blotting. Primary striatal neurons were fixed, and stained as described (4) . Western blotting was performed using whole-cell extracts from DIV14 striatal culture or purified nuclei from P10 rodent striata (4) . Antibody dilutions and sources for immunostaining and western blotting are as described (4, 5) Chromatin immunoprecipitation (ChIP). ChIP assays were performed largely as described (15) starting with ~5x10 6 cells. After crosslinking, lysates were immunoprecipitated with 2-4 μg of anti-Elk-1 or 2-4 μg of nonspecific IgG (Millipore Corporate, Billerica, MA) at 4°C overnight. Immune complexes were collected, washed, eluted, and reverse-crosslinked as described (15) . Eluted DNA was purified and used as a template for PCR. Primer sequences are given in Table  S1A .
Quantitative Reverse Transcriptase PCR. Two-step quantitative reverse transcriptase PCR (QRT-PCR) was performed using procedures and sets of primers described in the Supplemental Data. Expression levels of target mRNAs were normalized to Gapdh mRNA and expressed as fold change compared to the untreated control.
RESULTS

mGluR5 wild type but not deficient cultures exhibit agonist-specific Ca
2+ responsesRecently, we have shown that rat striatal mGluR5 can be expressed on nuclear membranes where it couples to G q/11 and phosphatidylinositide (PI)-phospholipase C (PLC) to generate inositol 1,4,5-triphosphate (IP 3 )-mediated release of Ca 2+ via Ca 2+ release channels in the nucleus (4, 5) . We have also shown that: 1) agonists such as glutamate and the Group 1 agonist, quisqualate (Quis), reach intracellular receptors via both sodium-dependent transporters and cystine/glutamate exchangers; 2) the Group 1 ligand, (S)-3, 5-dihydroxyphenylglycine (DHPG), does not compete with Quis or glutamate for uptake into the cell and therefore is a nontransported or impermeable agonist; and 3) the drugs LY395053 and LY367366 are nontransported, impermeable antagonists (4, 5, 16) .
To ensure the specificity of nuclear mGluR5 responses and to extend these results to murine systems, we prepared striatal cultures from genotyped P1 mouse pups derived from mating mice heterozygote for mGluR5. No mGluR5 immunoreactivity was seen in cultures prepared from mGluR5 null mice whereas robust staining could be visualized in wild type (+/+) neurons on processes, intracellularly, and on the nuclear membrane ( Figure 1A vs. 1C). Because Quis would also activate AMPA receptors and mGluR1, it was bath applied in the presence of 25 µM SYM2206, an AMPA receptor antagonist, and 20 µM CPCCOEt, an mGluR1 antagonist. Treatment under these conditions led to a rise in Ca 2+ in both the cytoplasm as well as the nucleus in mGluR5 +/+ cultures but not in null cultures ( Figure 1B vs. 1D). The same activation pattern was seen when Quis was perfused into cultures for short periods of time ( Figure S1A ). The lack of Quis-mediated Ca 2+ responses in null cultures shows that endogenous AMPA and/or NMDA receptors are not being activated ( Figure 1D ). Moreover, bath application of 50 µM AMPA in the presence of SYM2206 did not activate intracellular Ca 2+ in this system ( Figure S1B) . Finally, the inclusion of 50 µM D-APV, a competitive NMDA receptor antagonist did not affect Quis-mediated Ca 2+ responses ( Figure S1C ). Thus Quis-mediated effects are specific for mGluR5.
Quis-mediated Ca 2+ changes consisted of two phases, an initial rapid rise followed by a sustained elevation ( Figure 1B ). Both sets of responses were terminated by the addition of the permeable, mGluR5 antagonist, MPEP ( Figure 1B ) whereas cultures pre-incubated with the nontransported antagonists, LY393053 ( Figure 1E ) or LY367366 (not shown), followed by Quis exhibited the sustained Ca 2+ response pattern as cultures treated with Quis alone. In contrast, addition of the non-transported agonist, DHPG, to +/+ but not mGluR5 null cultures ( Figure S1H ) led to a rapid transient Ca 2+ peak which returned to base line following MPEP application at the height of the peak (not shown) or on its own, prior to MPEP addition ( Figure 1F ). In keeping with the finding that LY393053 and LY367366 block extracellular receptors (4, 5, 16) , bath application of either drug blocked DHPG responses ( Figure 1G ; and not shown). Compiled results from multiple experiments assessing drug-induced changes of both the initial Ca 2+ peak ( Figure S1D ) and from responses at 300 s ( Figure 1H ) revealed that Quis and DHPG generated unique Ca 2+ responses that were specific for mGluR5. To rule out the possibility that Quis and DHPG had different affinities for receptors expressed on cell surface or intracellular membranes, inhibition of radiolabeled glutamate binding was tested using Quis or DHPG together with plasma membrane or nuclear membranes ( Figure S1E, F) . No significant differences were found between drugs or membrane sources (DHPG plasma membrane IC 50 = 2.94 ± 1.71 μM; DHPG nuclei IC 50 = 2.86 ± 1.23 μM vs. Quis plasma membrane IC 50 = 2.75 ± 1.47 μM; Quis nuclei IC 50 = 1.56 ± 0.72 μM). These values are similar to those obtained by others (17) .
We also tested the striatal Ca 2+ response for the endogenous ligand, glutamate in the presence of the NMDA receptor antagonist MK801, the AMPA/Kainate receptor antagonist, CNQX, and CPCCOEt. The glutamate response in +/+ cultures exhibited the same profile as that of Quis ( Figure S1G ). Moreover, it was blocked by MPEP and completely absent in null cultures ( Figure S1G , H). Thus, like Quis, glutamate activates both cell surface and intracellular mGluR5. These data provide compelling proof as to the specificity of intracellular mGluR5-mediated Ca 2+ signals and demonstrate that activation of cell surface versus intracellular receptors leads to spatially and temporally distinct Ca 2+ responses.
Activation of intracellular but not cell surface mGluR5 increases phosphorylation of ERK1/2 -Amongst other things, agonist treatment of striatal mGluR5 results in ERK1/2, SAPK/JNK, and CaMKIV pathway activation ( Figure 2A ) (18) . To determine whether differential receptor activation leads to differential signaling responses, we treated rat striatal cultures with different ligands and pathway inhibitors. Significantly, Quis alone or Quis in the presence of either nontransported antagonist, LY393053 or LY367366 (not shown), upregulated phospho-ERK1/2 (pERK) within 5 minutes of treatment whereas pERK upregulation was not observed with DHPG ( Figure 2B , C).
Quis-mediated ERK1/2 phosphorylation could be blocked by MPEP or the MEK inhibitor U0126 but not by the CaMKK inhibitor, STO609 (Figure 2B, C). A possible role for CaMK involvement in ERK1/2 activation was underscored by the general CaMK inhibitor, KN62's inhibition of ERK1/2 phosphorylation (not shown) and the CaMKII inhibitor, KN93's partial inhibition ( Figure 2B , C). Western blotting showed that at no time point did DHPG significantly activate ERK1/2 whereas Quis increased ERK1/2 phosphorylation for 15 min before declining back to base line ( Figure 2D , E).
Activation of both cell surface and intracellular mGluR5 increases phosphorylation of JNK and CaMKIV -mGluR5 activation is also associated with JNK and CaMK activation (13).
Using both immunocytochemistry and western blotting we found that p38MAPK exhibited no change in any condition (not shown) and that phosphorylation of CaMKIV and JNK went up equally in response to either agonist ( Figure 3 ). Phospho-CaMKIV (pCaMKIV) was equally activated at 5 and 10 min by DHPG and Quis ( Figure 3C , D) although the Quis response peaked later and declined more slowly ( Figure 3D ). DHPG-mediated CaMKIV activation was blocked by MPEP, LY393053, KN62 as well as STO609, but not U0126 nor the CaMKII inhibitor, KN93 ( Figure 3A , B). Quis-mediated CaMKIV phosphorylation was essentially the same except that neither LY393053 nor LY367366 blocked Quis responses ( Figure 3A , B). Thus ligand occupation of cell surface and intracellular receptors not only activates similar pathways (JNK, CaMKIV) but also unique signaling molecules such as ERK1/2 phosphorylation.
Activation of intracellular versus cell surface mGluR5 increases Elk-1 phosphorylation -
Agonist stimulation of mGluR5 leads to the phosphorylation of several transcription factors including CREB and Elk-1 (13), hence we tested whether DHPG and Quis differentially increased Elk-1 phosphorylation (pElk-1) in striatal cultures. As shown in Figure 4A , B, Quis but not DHPG stimulated an ~8-fold increase in the number of mGluR5-positive neurons with detectable pElk-1 in the nucleus. This increase was entirely blocked by MPEP but not by LY393053 or LY367366 indicating that Elk-1 phosphorylation was due to intracellular receptor activation. Quis-mediated induction of Elk-1 was also apparent following western blotting of treated striatal lysates ( Figure  4C, D) . Because Elk-1 can be phosphorylated by ERK1/2, JNK, and CaMK cascades (Figure 2A ), we used pathway inhibitors to determine whether there were any preferential responses. U0126 and KN62 completely blocked Elk-1 phosphorylation whereas the p38MAPK inhibitor, SB202190, the JNK inhibitor, SP600125, the PKC inhibitor, GF109203X, or STO609 did not (Figure 4A , B; Figure S2A , B). KN93 partially blocked Elk-1 activation ( Figure 4A, B) , whereas dnCaMKK, dnCaMKI and dnCaMKIV did not ( Figure 4E, F) . Collectively, the most parsimonious model for these data is that a CaMKII/MEK/ERK1/2 cascade phosphorylates Elk-1 in response to signals originating from intracellular receptors versus those on the cell surface.
Activation of both intracellular and cell surface mGluR5 increases CREB phosphorylation -In contrast to Elk-1 induction, significant upregulation of phosphorylated CREB (pCREB) could be observed within 15 minutes of either Quis or DHPG application ( Figure 5A ). MPEP pretreatment blocked the effects of either drug whereas LY393053 only blocked DHPG ( Figure  5A ). Western blots confirmed equivalent agonistmediated phosphorylation of CREB which returned to baseline by 2 hours (Figure 5B, C) . Although not significantly different from each other, Quis generated more intense CREB responses then did DHPG particularly between 10 and 60 minutes ( Figure 5D ). Both STO609 and KN62 blocked agonist-mediated CREB phosphorylation whereas U0126, SB202190, SP600125, KN93 or GF109203X had no effect ( Figures 5A and S3A ). Consistent with these data, dnCaMKK and dnCaMKIV blocked pCREB formation whereas dnCaMKI did not ( Figure 5D , E). These observations support the notion that mGluR5 receptors utilize a CaMKK/CaMKIV cascade to phosphorylate CREB. ERK1/2 does not appear to play a role in this system. Finally, pERK1/2, pCREB and pElk-1 responses were specific to mGluR5 expressing neurons since striatal cultures derived from mGluR5 knock out animals exhibited no response ( Figure S3B ).
Activation of intracellular versus cell surface mGluR5 increases CaMKII phosphorylation -The pharmacological inhibitors, KN62 and KN93 support a role for Ca 2+ signaling pathways being involved in intracellular mGluR5 mediated Elk-1 phosphorylation. Because these drugs also have off-target effects and as dnCaMKI, dnCaMKIV, and dnCaMKK did not block this process ( Figure 4E,F) , we directly tested the notion that CaMKII is involved. Use of an anti-phospho CaMKII (pCaMKII) antibody showed robust activation of this kinase within five minutes of Quis but not DHPG treatment in either mGluR5 positive neurons and processes or in cell lysates prepared from striatal cultures ( Figure 6A-D) . The appearance of pCaMKII was blocked by MPEP but not by LY393053 indicating that intracellular receptors were involved in its activation ( Figure 6A, B) . Consistent with these data, dnCaMKII-EGFP expression in mGluR5 positive striatal neurons showed about a 50% decrease in Elk-1 phosphorylation compared with controls ( Figure 6 C, D vs. Figure 4B ) whereas mGluR5-activated pCREB was not blocked by dnCaMKII ( Figure 6G , H vs. Figure 5A ). Taken together these data confirm that a CaMKII/MEK/ERK1/2 cascade phosphorylates Elk-1 in response to signals originating from intracellular receptors versus those on the cell surface.
Nuclear Ca
2+ is sufficient for nuclear mGluR5-mediated ERK, Elk-1 and CREB activation but not CaMKIV -To test the hypothesis that nuclear Ca 2+ is sufficient and not just necessary for phosphorylating the various signaling components activated by mGluR5 agonists, we isolated nuclei from P10 rat striata and directly tested whether Quis or DHPG application would lead to phosphorylation of ERK, CaMKIV and subsequently Elk-1 and CREB. Since DHPG cannot cross the membrane (4,5) we predicted and indeed observed that DHPG treatment did not lead to the phosphorylation of ERK, Elk-1, CaMKIV or CREB whereas Quis led to a direct 1.5 -2-fold increase in all signaling molecules except for CaMKIV that could be blocked by MPEP, U0126, and KN62 (Figure 7A, B; and not shown). Western blots of nuclei prepared from striatal tissue treated with DHPG or Quis confirmed that only Quis increased ERK, CREB and Elk-1 phosphorylation, a response which could be blocked by MPEP, U0126, and KN62 (Figure 7C,  D; and not shown). Taken together, these data reenforce the notion that nuclear Ca 2+ is sufficient to induce ERK, CREB and Elk-1 phosphorylation in situ.
Activation of intracellular versus cell surface mGluR5 leads to differential activation of c-Fos and Egr1 promoters but not a CREcontaining promoter -
To test whether Elk-1 phosphorylation is associated with gene activation we determined whether the known Elk-1 targets cFos and Egr1 are affected by differential agonist treatment of striatal cultures. Both immediateearly genes were increased following Quis treatment but not with DHPG whereas c-Jun which lacks an Elk-1 binding site (19) was not induced at any time point ( Figure 8A) . A small but significant increase in Egr1 RNA levels was seen after 2 hr of DHPG treatment ( Figure 8A ) although DHPG-mediated changes in Egr1 promoter function were never seen ( Figure 8B, C) . (20) . Because CREB phosphorylation is upregulated equally in response to either drug ( Figure 5 ), we also tested a CREB response element (CRE)/luciferase construct as a positive control for either agonist (somatostatin CRE; CRE soma /luciferase) (21) . Both SRE c-Fos and SRE Egr1 were upregulated following 15 min of Quis but not DHPG treatment even in the presence of LY393053 ( Figure 8B ). As expected, the CRE soma construct was upregulated by both drugs ( Figure 8B ).
To determine whether Elk-1 is bound to the promoters of its target genes in living cells we used chromatin immunoprecipitation assays. Striatal cultures were treated with DHPG or Quis for 15 min and then cross-linked and processed essentially as described (15) . Primers for PCR amplification were designed to flank the SREs within the upstream regulatory regions of c-Fos and Egr1 as well as non-SRE-containing nearby introns. The presence of a PCR band of the predicted size in Quis-treated but not DHPG striatal extracts demonstrates that Elk-1 is directly binding to the SRE in the Egr1 and c-Fos promoters as a consequence of intracellular mGluR5 activation ( Figure 8C ). No such band is observed using intron primers validating the specificity of this response ( Figure 8C ).
Given that Quis-induced pElk-1 increases c-Fos mRNA, activates the c-Fos SRE and binds the c-Fos promoter in vivo, we tested whether Fos protein expression is similarly upregulated. Consistent with this notion, Quis but not DHPG induced Fos expression 30 minutes after agonist application (Figures 9A-D) . Quis-mediated Fos induction was blocked by MPEP and U0126 but not by the cell surface antagonist ( Figure 9A, B) . Further, Quis treatment but not DHPG, led to a delayed upregulation of Fos targets: Fosl1, Fosl2 and Fosb ( Figure 9E ). Collectively these data show that in the context of intracellular mGluR5 activation, Elk-1 binds to and activates its known targets which, in turn, activate their targets leading to a signaling cascade independent of cell surface signaling pathways.
DISCUSSION
G-protein coupled receptors are known for converting extracellular signals into intracellular responses. However, some receptors are also localized on intracellular membranes where they may play a unique role in the cell's physiology. Here we show that activation of cell surface mGluR5 via agonists that are not transported into the cell induces rapid, transient Ca 2+ responses whereas activation of intracellular mGluR5, leads to a more sustained response. Activation of CaMK pathways by either cell surface or intracellular receptors results in the phosphorylation of CREB whereas only intracellular receptor activation of ERK1/2 stimulates Elk-1 phosphorylation, increased mRNA of known Elk-1 targets, increased transcription of Elk-1 response elements fused to reporter genes and increased Elk-1 bound to Elk-1 response elements in vivo. These observations challenge the notion that environmental stimuli are transmitted to the cell's interior solely via gatekeeper proteins at the plasma membrane to bring about long term changes. Rather, these data suggest a major role for intracellular mGluR5 in the regulation of nuclear Ca 2+ , which is intimately associated with development, plasticity and survival. mGluR5-specific signaling pathways depend upon location -Because the Group 1 mGluRs play key roles in synaptic plasticity as well as various neurological and neurodevelopmental disorders, their signal transduction pathways have been examined in various cellular contexts. Evidence linking mGluR5 activation to ERK1/2 phosphorylation and the upregulation of CREB and Elk-1 has been demonstrated in different systems as well as in striatal tissue (13) . In some of these model systems DHPG did indeed activate ERK1/2 (18), a response we never observed in our striatal culture system. We do, however, see DHPG activation of ERK1/2 in hippocampal cultures which underscores the cell type specific nature of a given receptor's responses (V. Kumar, unpublished observation). It should also be noted that most DHPG "users" do not add additional antagonists to control for off-target effects thus conceivably ERK1/2 activation in previous studies might be generated from mGluR1 activation. Overall, however, our findings confirm and extend these earlier data, noting for the first time that CaMKs, JNKs and CREB are readily activated by both cell surface and intracellular receptors whereas the MEK/ERK1/2, Elk-1 cascade is activated only by agonists that can access intracellular receptors such as glutamate and Quis.
Using pharmacological inhibitors as well as dnCaMKK and dnCaMKIV the present findings support a role for Ca 2+ signaling pathways in mediating CREB phosphorylation. Because the dnCaMKI did not block CREB phosphorylation, a recently described CaMKK/CaMK1 pathway (14) seems unlikely to be part of this cascade. Instead, mGluR5-activated CaMKK either translocates to the nucleus to activate CaMKIV or conversely releases inactive CaMKIV which itself moves to the nucleus. Moreover, as KN62 completely and KN93 partially blocked ERK1/2 and Elk-1 phosphorylation whereas PKC inhibitors did not, it seems likely that CaMKs also play a role in activating factors upstream of ERK1/2. CaMKII appears to fulfill this function since 1) pCaMKII was rapidly observed after Quis but not DHPG treatment ( Figure 6A-D) , 2) dnCaMKK, dnCaMKI and dnCaMKIV did not block Elk-1 phosphorylation ( Figure 4E ) but 3) dnCaMKII blocked at least 50% of Elk-1 phosphorylation ( Figure 6E, F) . The partial blockade by the dnCaMKII is in agreement with the KN93 data implying that either other CaMKII subtypes or even other kinases might be involved. Interestingly, CaMKII can directly activate Ras and/or Raf1 (22) which are upstream of MEK. As a critical sensor for Ca 2+ in the brain, CaMKII can be found in a plethora of homo-or heteromultimers of different subunits and splice forms some of which are found in the nucleus (23). The observation that KN62 blocks nuclear activation of ERK1/2 and Elk-1 suggests that some form of CaMKII may already be within the nucleus triggering the activation of Raf or MEK. A proposed model based on current findings as well as published reports is shown in Figure 10 . Although further studies are necessary to confirm aspects of this model, the immunocytochemical, molecular and pharmacological data presented here are all consistent with each other.
mGluR5-induced nuclear Ca
2+ -Increased cell surface synaptic activity is linked to nuclear Ca 2+ changes underlying gene transcription and plasticity (24) . Many cell biological studies, however, have also shown that Ca 2+ can be directly released from the nuclear envelope (8 signal is dissipated back across the nuclear pore complex (7) . For example, glutamate gave rise to nuclear transients almost a second faster then could be measured in the cytoplasm of mGluR5 expressing HEK cells whereas DHPG stimulated cytoplasmic Ca 2+ transients half a second faster than in the nucleus (4) . Although these studies were done in heterologous cells, nevertheless they establish the precedent that a signal-induced transient could start in the nucleus and be transmitted to the cytoplasm (4). This idea is supported by recent studies showing that hepatocyte growth factor binds to its receptor, cmet, at the plasma membrane. Subsequently, cmet, a receptor tyrosine kinase, rapidly translocates to the nucleus where it generates IP 3 , increasing Ca 2+ concentrations in the nucleus which then invade the cytoplasm (25) . Additional evidence comes from tobacco BY-2 cells where long chain based sphingolipid derivatives specifically mobilize Ca 2+ originating in the nucleus not the cytoplasm (26) . These data support the notion that the nucleus itself may serve as a center for Ca 2+ dissemination. Additional support for the nucleus serving as an independent signaling unit comes from our findings that ERK1/2, Elk-1, and CREB were all phosphorylated in situ ( Figure 7 ). Presumably this is due to the presence of upstream kinases like Raf and MEK which are within the nucleus and capable of phosphorylating their downstream targets (27) . Only CaMKIV was not significantly by guest on May 2, 2016 http://www.jbc.org/ Downloaded from phosphorylated following activation of nuclear mGluR5s suggesting that a necessary cytoplasmic step was missing (Figure 7 ). How then is nuclear CREB phosphorylated? Akin to the model described by (28) , it may be that CaMK signaling to the ERK1/2, MAPK pathway underlies this observation. Indeed, both U1026 and KN62 blocked pCREB induction. Because the nucleus exhibited diminished responses in comparison with the level of activation measured when cell surface and intracellular mGluR5s were stimulated (Figure 7 vs. Figures 3-5) , critical information coming from the cytoplasm also appears necessary. Presumably, activation of multiple signaling cascades individually contributes information in terms of speed, amplitude or signal duration. Thus the nucleus may serve not only as a point of convergence for cytoplasmic signals but as an originator of its own. Intracellular glutamate -The data shown here emphasize that the endogenous neurotransmitter, glutamate, not only activates a myriad of receptors and transporters at the cell surface but that within the cell it also activates these very same proteins as long as it can access their ligand binding domains. One possible caveat to the idea that glutamate activates intracellular receptors is the hypothesis that intracellular glutamate concentrations are very high, hence intracellular receptors would be maximally activated or desensitized already. However, numerous studies have demonstrated that glutamate is highly compartmentalized in neurons (30). Techniques such as 13 C-NMR, 13 C-and/or 15 N-GC/MS provide compelling evidence that glutamate has many fates within the cell and that a large proportion of extracellular glutamate is transaminated and enters the mitochondria where it serves as a substrate for the TCA cycle (30,31). Moreover, anti-glutamate immunogold electron microscopy studies indicate that particles representing glutamate are clustered over cytoplasmic organelles such as mitochondria, ER, and the nucleus.
Moreover, the neuronal glutamate transporter, EAAT3, may play a significant role in the compartmentation of glutamate. For example, only about 20% of EAAT3 is on the cell surface; the rest is localized in cytosolic compartments from which it can be rapidly mobilized in response to a variety of stimuli (32). Even after mobilization, about 60% of EAAT3 is still associated with intracellular membranes (33). Thus, many factors modulate glutamate metabolism including transporter distribution, fluctuation of metabolite concentration, and regulation of the many enzymes involved in glutamate metabolism (phosphate-activated glutaminase, glutamate dehydrogenase, malate dehydrogenase, aspartate aminotransferase, etc.) (30). Therefore, it is likely that both neuronal glutamate metabolism and its compartmentation are highly complex.
In summary, these studies suggest a major role for nuclear mGluR5 receptors in the regulation of nuclear Ca 2+ . Given that mGluR5 plays important roles in development, synaptic function and learning and memory as well as pathological roles in Fragile X syndrome, anxiety, addiction, and PD, understanding the long term consequences of intracellular receptor activation might lead to novel therapeutic strategies for these disorders.
Tokumitsu for the monoclonal anti-CaMKIV antibody. 
